Incyte Corporation (INCY)vsBeiGene, Ltd. (ONC)
INCY
Incyte Corporation
$92.23
+1.78%
HEALTHCARE · Cap: $18.03B
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 4% more annual revenue ($5.34B vs $5.14B). INCY leads profitability with a 25.0% profit margin vs 5.4%. INCY trades at a lower P/E of 14.1x. INCY earns a higher WallStSmart Score of 83/100 (A-).
INCY
Exceptional Buy83
out of 100
Grade: A-
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.0%
Fair Value
$299.99
Current Price
$92.23
$207.76 discount
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Every $100 of equity generates 30 in profit
Keeps 25 of every $100 in revenue as profit
Attractively priced relative to earnings
Strong operational efficiency at 25.6%
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
No major concerns identified
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : INCY
The strongest argument for INCY centers on PEG Ratio, Altman Z-Score, Return on Equity. Profitability is solid with margins at 25.0% and operating margin at 25.6%. Revenue growth of 27.8% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : INCY
No major red flags identified for INCY, but monitor valuation.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
INCY profiles as a growth stock while ONC is a hypergrowth play — different risk/reward profiles.
INCY carries more volatility with a beta of 0.84 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
INCY generates stronger free cash flow (521M), providing more financial flexibility.
Bottom Line
INCY scores higher overall (83/100 vs 42/100), backed by strong 25.0% margins and 27.8% revenue growth. Both earn "Exceptional Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?